Chemistry:Bivatuzumab mertansine
From HandWiki
Short description: Chemical compound
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD44 v6 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| ChemSpider |
|
  (what is this?) (verify) | |
Bivatuzumab mertansine is a combination of bivatuzumab, a humanized monoclonal antibody, and mertansine, a cytotoxic agent. It is designed for the treatment of squamous cell carcinoma.[1]
References
- ↑ "A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus". Clinical Cancer Research 12 (20 Pt 1): 6064–72. October 2006. doi:10.1158/1078-0432.CCR-06-0910. PMID 17062682.
 |  |
